Agenda

The event design includes engaging debates, panels and roundtable discussions to foster interaction between participants and stimulate them to search for solutions to the real challenges and opportunities in the industry that will enable change.

PRELIMINARY Agenda

(Subject to change)

MONDAY 13 NOVEMBER 2017

16:00-18:00	THE DEBATE: CONTROVERSIES IN PRECISION MEDICINE Moderators: Dan Peer, Martin Lohse, Christian Elze We will introduce why and how we are at point of controversies today. The opening debate will explore whether a genetic-driven approach just needs more time to produce results or whether we need to first invest more in a regulatory filtering of genetic variations. Read more about the speakers here> WELCOME FROM SUMMIT CHAIRPERSON Dan Peer Director, Tel Aviv University Cancer Biology Research Center, Tel Aviv, Israel OPENING ADDRESS Martin Lohse Chair of the Board of Directors and Scientific Director of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association Member of the Board of Directors of the Berlin Institute of Health (BIH), Berlin, Germany Debaters: Richard Fitzgerald Director, Clinical Research Unit, RLUH, Liverpool, UK Denis Noble Emeritus Professor of Cardiovascular Physiology, Oxford, UK Panel Discussion with Audience Questions
18:00-19:00	BUSINESS PERSPECTIVE How to bring precision medicine to fields outside of oncology, mendelian rare diseases and infection diseases. We will review what has worked or not worked to date and therefore factors we need to be considering in moving forward. We will hone-in on how to approach building more viable businesses in precision medicine. Read more about the speakers here> Christian Elze Senior Partner Catenion, London, UK Robert Wasserman Chief Medical Officer at Northern Biologics, Toronto, Canada
19:00	NETWORKING RECEPTION

TUESDAY 14 NOVEMBER 2017

8:30-10:15	PRECISION MEDICINE - THE PHARMACEUTICAL STANDPOINT Pre-Disease Intervention: Bringing Precision Medicine from the Back End to the Front End of Diseases. We will focus on how industry perceives the current challenges in precision medicine and their outlook based on specific case studies. Read more about the speakers here> Speakers: Thomas Bock Chairman and Chief Executive Officer HeritX, Santa Monica, USA Matthias Ocker Head of Biomarker Strategy, Bayer AG, Berlin, Germany Ludwig Heesen Project Manager Clinical Studies, BioNTech, Mainz, Germany Round Table Discussions
10:15-10:45	Coffee Break, Networking & Exhibition
10:45-12:55	PRECISION MEDICINE IN THE CLINIC - CLINICAL STANDPOINT *Case Studies & Panel Discussion on the clinical benefit* We will seek to understand when a precision medicine approach will be beneficial and when it is unlikely to be so. If we can increase our understanding, then we can better focus on increasing the efficiency of precision medicine based drugs. Read more about the speakers here> Chair: Michael Heuser Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany Speakers: Ido Wolf Head, Oncology Division, Tel Aviv Medical Center, Tel Aviv, Israel Michael Heuser Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany Pia Raanani Head of The Hematology Devision in Rabin Medical Center, Tel Aviv, Israel Ulrich Keilholz Acting Director, Charité Comprehensive Cancer Center, Berlin, Germany Round Table Discussions
13:00-14:00 Lunch, Networking & Exhibition
14:00-15:45	PATIENT STRATIFICATION VIA GENOMICS/EPI-GENOMICS IN CANCER Through the power of genomics and epi-genomics, we are starting to see some success in patient stratification for treating cancer. However, we currently lack the necessary tools to fully process and analyse the data in many cases, such as when multiple patients' phenotype data does not correspond to shared genome level mutations. How can we improve our data and what next steps do we need in clinical informatics? Read more about the speakers here> Speakers: Erez Levanon Associate Professor at The Mina and Everard Faculty of Life Sciences, Bar-Ilan University Ramat Gan, Israel Xiangdong Wang Director Shanghai Institute Clinical Bioinformatics, Fudan University Zhongshan Hospital, Shanghai, China Manfred Dietel Full Professor and Director of the Institute Charité, Berlin, Germany Deepak Asudani Associate Clinical Professor of Medicine, Vice Chief, Clinical Operations, Division of Hospital Medicine, University of California San Diego, USA Round Table Discussions
15:45-16:15	Coffee break, Networking & Exhibition
16:15-18:00	DEVELOPING NEW DELIVERY VEHICLES FOR PRECISION MEDICINE Much of the potential of precision medicine rests on drug delivery strategies. What is achievable with current drug carriers and where do we need to focus in our current pipeline? How can precision medicine benefit from nanomedicine? And if the future of precision medicine lies in altering nucleic acid, then where do we need to focus our research to make it a reality? Read more about the speakers here> Speakers: Heinrich Haas Vice President RNA Formulation & Drug Delivery at BioNTech RNA Pharmaceuticals, Mainz, Germany James Taylor Co-founder, CEO at Precision NanoSystems, Inc., Vancouver, Canada Twan Lammers Head of department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany Round Table Discussions
18:00-19:15	THE FUTURE OF PRECISION MEDICINE FROM A REGULATORY STANDPOINT Regulatory agencies will present their view on the emerging field of precision medicine and what they are seeing as the needed criteria to ensure a fair and efficient approval process. Read more about the speakers here> Speakers: Khaled Bouri Science Advisor Office of Regulatory Science and Innovation, Food and Drug Administration, Silver Spring, USA Christopher Rowe Innovation Lead, Precision Medicine, Innovate UK, Swindon, UK

WEDNESDAY 15 NOVEMBER 2017

08:30-10:15	DISEASE SIGNATURE AND SMALL VS. BIG DATA IN PRECISION MEDICINE This session will review the challenges of operating without an aligned definition of disease signature. We will consider the amount of data we are processing, both small and big data, as well as whether we should be taking advantage of clinical trials to collect as much real-time physical and environmental data. Read more about the speakers> Speakers: Mira Marcus-Kalish Director, International Research Affairs, Tel-Aviv University Ramat Aviv, Tel Aviv, Israel Ancha Baranova Associate Professor, School of Systems Biology, George Mason University, Fairfax, USA Noam Shomron Filtering Big Data, Finding Small Molecules, that Lead to Precision Medicine in Breast Cancer Round Table Discussions
10:15-10:45	Coffee Break, Networking & Exhibition
10:45-12:30	HEALTH INFORMATICS How do we analyse complex diseases? Are computer-based solutions such as AI and machine learning the best solution direction? What is their potential and limitations? Read more about the speakers here> Speakers: Harsha Rajasimha Global Head, Life Sciences R&D, NTT DATA Inc., Washington, USA Sahar Gelfman Institute for Genomic Medicine, Columbia University Medical Center, New York, USA Edit Buzas Professor and Chair at Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary Round Table Discussions
12:30-13:30	Lunch, Networking & Exhibition
13:30-14:30	THE POWER OF PRECISION MEDICINE IN RARE DISEASE *Panel discussion: The Role of Foundations in Precision Medicine* The field of rare diseases is expanding to the point of more than 10,000 sub-diseases. There is a lack of single drugs suitable for enough of these sub-diseases, which has made the drug discovery process less financially attractive and riskier for pharma. The challenge for precision medicine is to develop a global drug solution where there is a common denominator. Where are we at and how can the market move forward? Read more about the speakers> Panellists: Peter Kapitein President and Patient Advocate Inspire2Live, Amsterdam, Netherlands Janet Allen Director of Strategic Innovation at Cystic Fibrosis Trust, London, UK Lior Dor Founder of Ran’s smile – the Israeli STXBP1 foundation, Rehovot, Israel
14:30-16:15	NEW THERAPEUTIC MODALITIES FOR RARE DISEASE Is there potential for a new protein or messenger RNA that will fit all mutations and generate a global solution for a disease? Case studies on this and other novel approaches for treating rare diseases. Read more about the speakers> Speakers: Eran Blaugrund VP R&D, ART BioScience Ltd, Rehvot, Israel Stuart Hughes Director and Head of Pharmacology at Vertex Pharmaceuticals, London, UK Thomas Wilckens CEO at InnVentis Ltd., Kadima, Israel Round Table Discussions
16:15-16:45	Coffee break, Networking & Exhibition
16:45 - 17:15	CLOSING - SUMMARY & DISCUSSION Panel Discussion on the next steps for precision medicine. Summary of where are the challenges and what are the potential solutions.

Download Programme